Solara Active Pharma Sciences Ltd., incorporated in the year 2017, is a Small Cap company (having a market cap of Rs 5927.33 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 31-03-2021, the company reported a Consolidated Total Income of Rs 453.99 Crore, up 4.37 % from last quarter Total Income of Rs 434.98 Crore and up 46.97 % from last year same quarter Total Income of Rs 308.90 Crore. Company reported net profit after tax of Rs 56.61 Crore in latest quarter.
Investment Rationale
The brokerage values SOLARA at 13x 12M forward EBITDA, factoring in a) favourable prospects in the API industry, b) cost efficiency driving market share leadership in base products, c) upside from ALS merger, d) wide portfolio offerings, e) diversified facilities, and f) encouraging CRAMS opportunity.
Promoter/FII Holdings
Promoters held 44.1 per cent stake in the company as of March 31, 2021, while FIIs held 13.7 per cent, DIIs 4 per cent and public and others 38.3 per cent.
